Epigenetics and CSC Regulation

Epigenetic modifications play a pivotal role in maintaining CSC properties, including their self-renewal and differentiation potential. This track delves into how changes in DNA methylation, histone modifications, and non-coding RNAs regulate the stemness of CSCs. Understanding these epigenetic mechanisms is critical for identifying how CSCs evade traditional therapies and drive cancer progression. Researchers in this area explore how reversible epigenetic changes allow CSCs to adapt to different microenvironmental conditions and therapeutic pressures, leading to heterogeneity within the tumor. Epigenetic drugs, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, are being studied for their potential to disrupt CSC function and sensitize them to treatment, offering a new avenue for targeting CSC-driven cancers.

    Related Conference of Epigenetics and CSC Regulation

    April 28-29, 2025

    35th Experts Meet On Cancer Research & Therapy

    Paris, France
    May 26-27, 2025

    15th World Congress on Breast Cancer

    Rome, Italy
    June 16-17, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    July 14-15, 2025

    5th World Congress on Breast Cancer

    Berlin, Germany
    July 28-29, 2025

    45th Euro Congress on Cancer Science & Therapy

    Paris, France
    August 18-19, 2025

    6th Cancer Diagnostics & Treatment Conference

    Rome, Italy
    October 13-14, 2025

    8th International Conference on Anti-Cancer Drugs & Therapies

    Aix-en-Provence, France
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain
    November 24-25, 2025

    43rd World Cancer Conference

    Barcelona, Spain

    Epigenetics and CSC Regulation Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in